Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)

Stock Information for Eton Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Eton Pharmaceuticals Inc.

Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th
Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th
Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results
Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference
Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results
Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.